Search

Bruton tyrosine kinase (iBTK) inhibitors are effective drugs used in the treatment of various B-cell hemopathies, including ibrutinib; the first generation iBTK for which there is the most data available. Cardiovascular toxicities associated with the use of ibrutinib, including cardiac arrhythmia due to atrial fibrillation and hypertension, quickly emerged as a potential issue with iBTK, and especially from the first clinical trials with this molecule. Other rarer types of cardiovascular toxicities are increasingly described with ibrutinib. More recently, acalabrutinib and zanubrutinib have been developed as 2nd generation iBTK with greater selectivity for the BTK target and with the prospect of less adverse effects due to inhibition of off-target protein kinases. This work represents a brief literature review on cardiovascular toxicities associated with iBTK. [ABSTRACT FROM AUTHOR]